Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentaxim booster given with tetravalent dengue vaccine in healthy toddlers in Mexico
2014-001736-11Phase 3
- Sponsor
- Sanofi
- Start
- May 2014
- Modality
- Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dengue fever comparing Pentaxim + CYD dengue vaccine with Pentaxim + placebo (2 arms). Primary endpoints: Diphtheria, tetanus, polio, and Hib immunogenicity and Pertussis immunogenicity.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccineCYD dengue vaccine
03
Conditions
dengue fever
Beyond the preview
Go deeper on 2014-001736-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001736-11.